# Advisor Review - GPT-5-mini

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5-mini
**Paper:** paper.pdf
**Timestamp:** 2026-02-03T19:21:22.432164
**Route:** OpenRouter + LaTeX
**Tokens:** 18480 in / 1841 out
**Response SHA256:** 8506e7886ba85525

---

I reviewed the LaTeX draft for fatal errors under the four mandated categories (Data-Design Alignment, Regression Sanity, Completeness, Internal Consistency). I focused only on the kinds of errors you instructed me to catch and did not comment on prose, contribution, or minor choices.

Findings: I found no fatal errors.

Checks performed (high-level summary of what I verified)
- Data‑design alignment
  - The ACS PUMS years used are 2017–2019 and 2021–2022 (2020 excluded) and the paper consistently treats states that adopted in 2023–2025 as not-yet-treated in the observed sample. The maximum treatment year listed (some adoptions in 2023–2025) is explicitly coded as not-yet-treated for the analysis because those adoptions occur after the last observed ACS year (2022); the manuscript documents this coding choice and justifies it. The paper therefore does not claim to estimate post-2022 treatment effects while lacking data for those years.
  - For staggered DiD cohorts present in the data, there are post‑treatment observations in the sample (e.g., 2022 adopters have 2022 as the first treated year and 2021 as pre), and the author explains the use of t = g comparisons for mid-year adoptions given ACS lacks month-of-interview. I do not see a data–timing contradiction that would make the empirical design impossible.
  - Treatment definition and cohort coding are described consistently across sections (states adopting in 2021–2022 coded as treated; 2023+ coded as not-yet-treated in the sample). The paper repeatedly documents the same 29 treated / 22 not-yet-treated split; I found no mismatch between tables/text regarding which cohorts are treated in the analyzed years.

- Regression sanity
  - Reported coefficients and standard errors presented in text and small tables are plausible for the outcomes (percentage‑point changes with SEs in the 0.8–2.3 pp range). I did not find any reported SEs or coefficients that violate the sanity thresholds you specified (e.g., SEs >1000, coefficients >100, negative SEs, NaN/Inf, R² outside [0,1]). The individual-level TWFE table in the appendix reports coefficient and standard error magnitudes that are internally consistent.
  - Event‑study and Goodman‑Bacon decomposition summaries are reported with reasonable magnitudes and weights; nothing in those reported numbers triggers the “obviously broken” criteria.

- Completeness
  - I inspected the LaTeX source for placeholder tokens (NA, TBD, TODO, XXX, PLACEHOLDER) and found none.
  - Key elements required for a quantitative empirical paper are present or explicitly discussed: sample sizes are reported (main sample and by-year table in the appendix), standard errors are reported and clustered by state where indicated, placebo and subgroup analyses are described and summarized, and the paper documents sources for treatment dates. The manuscript also explicitly notes limitations (missing 2023 data) and proposes follow-up designs.
  - The manuscript uses \input{} for some tables/figures. In the LaTeX source provided these are external file references (e.g., \input{tables/tab2_main_results}). I treated the draft content and the numerical summaries quoted in the text/appendix as the available results; there are no explicit numeric placeholders inside the visible source that would indicate an unfinished analysis.

- Internal consistency
  - Numbers quoted in the text (e.g., total postpartum N = 169,609; sample sizes by year in the appendix that sum to that total) match across sections.
  - Treatment timing and cohort definitions are used consistently across the methods, data, and results sections.
  - Specification descriptions align with reported results (e.g., use of Callaway‑Sant'Anna for group‑time ATTs, state-year panel for aggregation, individual-level TWFE robustness checks).

Minor notes (non-fatal; no action required before submission, but worth being aware of)
- Small textual inconsistency: the abstract opens with "Between 2021 and 2025, 48 U.S. states adopted..." while later the manuscript more precisely frames adoption as 49 jurisdictions (48 states + D.C.). This is a minor wording inconsistency (states vs jurisdictions) but not a fatal error for data/analysis.
- The manuscript relies on t = g comparisons for 2022 adopters because of ACS lacking interview month; the paper explains this attenuation concern. This is an acknowledged limitation rather than an error, but you should ensure reviewers understand the measurement error implications (you already discuss attenuation).

Conclusion
- I did not find any fatal errors in the categories you required me to check. The empirical design is coherent with the data coverage as described; reported regression output that appears in-text and in appendices is numerically plausible; no placeholder or missing-key-element problems were detected; and claims are consistent with the provided evidence.

ADVISOR VERDICT: PASS